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Methionine adenosyltransferase (MAT) catalyzes the
synthesis of S-adenosylmethionine (AdoMet), the main
alkylating agent in living cells. Additionally, in the liver,
MAT is also responsible for up to 50% of methionine
catabolism. Humans with mutations in the gene MAT1A,
the gene that encodes the catalytic subunit of MAT I and
III, have decreased MAT activity in liver, which results
in a persistent hypermethioninemia without homo-
cystinuria. The hypermethioninemic phenotype associ-
ated with these mutations is inherited as an autosomal
recessive trait. The only exception is the dominant mild
hypermethioninemia associated with a G-A transition at
nucleotide 791 of exon VII. This change yields a MAT1A-
encoded subunit in which arginine 264 is replaced by
histidine. Our results indicate that in the homologous
rat enzyme, replacement of the equivalent arginine 265
by histidine (R265H) results in a monomeric MAT with
only 0.37% of the AdoMet synthetic activity. However
the tripolyphosphatase activity is similar to that found
in the wild type (WT) MAT and is inhibited by PPi. Our
in vivo studies demonstrate that the R265H MAT I/III
mutant associates with the WT subunit resulting in a
dimeric R265H-WT MAT unable to synthesize AdoMet.
Tripolyphosphatase activity is maintained in the hybrid
MAT, but is not stimulated by methionine and ATP, in-
dicating a deficient binding of the substrates. Our data
indicate that the active site for tripolyphosphatase ac-
tivity is functionally active in the monomeric R265H
MAT I/III mutant. Moreover, our results provide a mo-
lecular mechanism that might explain the dominant in-
heritance of the hypermethioninemia associated with
the R264H mutation of human MAT I/III.
Methionine adenosyltransferase (MAT,1 EC 2.5.1.6.) is a key
metabolic enzyme that catalyzes the synthesis of the most
important biological alkylating agent, S-adenosylmethionine
(AdoMet) (1). The synthesis of AdoMet occurs in a two-step
reaction. In the first step AdoMet and PPPi are synthesized
from the substrates methionine and ATP. Subsequently the
tripolyphosphate generated is hydrolyzed to PPi and Pi before
the products of the reaction are released (2, 3). The function of
the tripolyphosphatase activity in the overall reaction cata-
lyzed by MAT is still under discussion (4). In mammalian
tissues three forms of MAT have been described that are the
products of two distinct genes (5–8). The gene MAT2A encodes
a 396-amino acid catalytic subunit expressed in extrahepatic
tissues, as well as in fetal liver and hepatocarcinoma, that
associates with a regulatory b subunit to form MAT II (6, 9).
The gene MAT1A encodes a 395-amino acid subunit, expressed
in adult liver, that organizes into dimers, MAT III, and tetram-
ers, MAT I (5, 10–14). The reason for the presence of these two
different isoenzymes in liver has not been yet elucidated, al-
though it may be an adaptation to the metabolic requirements
of the liver. The liver has the highest specific activity of MAT,
which agrees with the observation that up to 85% of all meth-
ylation reactions and as much as 50% of methionine catabolism
occur in this tissue (15). Based upon the different kinetic prop-
erties of MAT I and MAT III isoforms, MAT III has been
considered the liver-specific enzyme. While MAT I, similarly to
MAT II in extrahepatic tissues, may maintain the basal
AdoMet levels required by cells, MAT III would be responsible
for the clearance of methionine after a load of this amino acid.
Two decades or more ago, it was observed that several new-
born children, screened for hypermethioninemia as an indica-
tor of homocystinuria due to a deficiency in cystathionine
b-synthase activity, presented a persistent hypermethionine-
mia with normal plasma levels of homocystine and tyrosine
and without severe liver disease (16–19). Enzymatic studies
demonstrated that the origin of this isolated persistent hyper-
methioninemia was a severe depletion of MAT activity in liver,
whereas the activity of MAT II in erythrocytes, lymphocytes,
and fibroblasts of these individuals was normal (16, 17, 19, 20).
Clinical and metabolic features in more than 30 such patients
have been described (20–23). The characterization of the hu-
man MAT1A gene led to the detection of 17 different mutations
that cause the previously reported depletion of MAT activity in
liver (24–28), designated, therefore, as MAT I/III deficiency.
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Segregation and mutation analysis revealed that in most of the
individuals with MAT1A mutations the hypermethioninemic
phenotype is transmitted as an autosomal recessive trait (22–
25, 28). However, a dominant inherited form of this abnormal-
ity has been reported in five families (21, 22, 26, 28–30). In
each such family a G-A transition at nucleotide 791 was de-
tected in one MAT1A allele. This change results in a MAT in
which arginine 264 is replaced by histidine (26). Crystallo-
graphic studies of Escherichia coli and recombinant rat liver
MAT show that the equivalent arginine 244 or 265, respec-
tively, is located in the interface between the two subunits of
the dimeric enzyme and is involved in a salt bridge with glu-
tamic 42, or the homologous 58 in the rat enzyme, of the
symmetric subunit, which contributes to the stabilization of the
oligomeric state of MAT (31, 32, 40). Moreover, arginine 244
contributes to each active site and is located in the immediate
vicinity of the polyphosphate group of ADP (4, 31). It has been
shown that replacement of arginine 264 by histidine in human
MAT inactivates the enzyme. Moreover, it has been proposed
that this mutation hinders normal oligomeric formation (26).
However, substitution of arginine 244 by leucine or histidine in
E. coli MAT resulted in an inactive enzyme, which, in contrast,
remains tetrameric with no apparent changes in the secondary
structure (4). To understand the biochemical basis of the dom-
inant inheritance of the phenotype associated with the R264H
mutation of human MAT I/III, we have purified and character-
ized the homologous rat R265H MAT I/III mutant. Our data
indicate that the active site for the tripolyphosphatase activity
is functionally active in the monomeric R265H MAT I/III mu-
tant and provide a molecular mechanism that might explain
the dominant inheritance of the hypermethioninemia associ-
ated with the R264H mutation in human MAT I/III.
EXPERIMENTAL PROCEDURES
Materials—Columns and chromatography media were from Amer-
sham Pharmacia Biotech. AdoMet was from Boehringer Ingelheim
(Knoll). All other reagents were from Sigma.
Site-directed Mutagenesis—A 1.2-kilobase fragment containing the
rat MAT1A coding region (33) was subcloned into a pET vector. The
resulting plasmid includes a 59-sequence that encodes for 6 histidine
residues and a thrombin cleavage site in frame with the rat liver
MAT1A coding region. Mutants were obtained by inverse polymerase
chain reaction according to the procedure of Pe´rez-Mato et al. (34). The
mutants were identified by sequencing the complete MAT cDNA.
Expression and Purification of His-tagged WT and MAT I/III Mu-
tants—WT and MAT I/III mutants were overexpressed in E. coli
BL21(DE3) as described previously (33). Recombinant His-tagged WT
and MAT I/III mutant proteins were purified from the bacterial cyto-
solic extracts by affinity chromatography on a Ni21-Sepharose column
equilibrated in 50 mM Tris/HCl, pH 8, 0.5 M NaCl, 75 mM imidazole.
Elution was performed using a linear gradient from 75 to 500 mM
imidazole in the same buffer. His-tagged MAT I/III proteins elute from
the Ni21 column at 250 mM imidazole. Protein purity was always more
than 95% as estimated by SDS-PAGE (35). Imidazole was removed by
dialysis against 10 mM Tris/HCl, pH 7.5, 150 mM KCl, 5 mM DTT. No
changes in the fluorescence, CD spectra, oligomeric state, and enzy-
matic activity were observed after digestion of the recombinant proteins
with thrombin (data not shown). Therefore all the assays were carried
out using the His-tagged recombinant proteins.
Association between WT and R265H MAT I/III Mutant Sub-
units—To study the formation of heterodimers in vivo, bacteria were
cotransformed with the plasmid pSSRL (12) to produce the WT MAT
subunit and a pET vector with the coding region of the R265H MAT
mutant to produce a His-tagged protein. His-tagged proteins were pu-
rified from the cytosolic extracts of cotransformed bacteria following the
procedure indicated above. The molecular mass of the purified protein
was estimated by size exclusion chromatography. To assess the subunit
composition, the recombinant protein was denatured by incubation
with 5 M urea in 50 mM Tris/HCl, pH 7.5, 150 mM KCl, 10 mM MgCl2, 5
mM DTT. Then, the mixture was chromatographed on a 1-ml Ni21-
Sepharose column equilibrated with 50 mM Tris/HCl, pH 8, 0.5 M NaCl,
75 mM imidazole. After loading the sample, the column was washed
with 10 column volumes of the same buffer. Elution was carried out
with 5 column volumes of 50 mM Tris/HCl, pH 8, 0.5 M NaCl, 0.5 M
imidazole, and 0.5-ml fractions were collected. Protein elution was
monitored by measuring the absorbance at 280 nm. The protein-con-
taining fractions were pooled, and aliquots were analyzed by size ex-
clusion chromatography and SDS-PAGE (35). Heterodimer formation
was also tested in vitro in two ways. In the first, MAT III purified from
rat liver was incubated with equimolar concentration of the R265H
mutant His-tagged protein (0.2 mg/ml) in 50 mM Tris/HCl, pH 7.5, 150
mM KCl, 10 mM MgCl2, 5 mM DTT for 30 min at 25 °C. Alternatively,
MAT III purified from rat liver was denatured by incubation with 5 M
urea in 50 mM Tris/HCl, pH 7.5, 150 mM KCl, 10 mM MgCl2, 5 mM DTT,
and then refolded by 20-fold dilution (the final concentration of WT
MAT subunits was 0.6 mM) in the same buffer containing a 3-fold molar
excess of His-tagged R265H MAT I/III mutant subunit, followed by
incubation for 30 min at 25 °C. The two mixtures were then re-purified
on a Ni21 column as indicated above. Imidazole was removed from the
retained fractions using a 5-ml Hi-trap desalting cartridge. Protein was
then denatured by adding urea to a final concentration of 5 M and
chromatographed again on a 1-ml Ni21-Sepharose column equilibrated
with 50 mM Tris/HCl, pH 8, 0.5 M NaCl, 75 mM imidazole. Flow-through
and imidazole eluted fractions were analyzed, in both experiments, by
SDS-PAGE (35).
Purification of MAT from Rat Liver—MAT III was purified from rat
liver according to the procedure described previously (36). Protein pu-
rity was more than 95% as estimated by SDS-PAGE (35).
Size Exclusion Chromatography—Protein samples were analyzed us-
ing a Superdex 200 HR 10/30 column equilibrated with 50 mM Tris/HCl,
pH 7.5, 150 mM KCl, 10 mM MgCl2 in an AKTA fast protein liquid
chromatography (Amersham Pharmacia Biotech). After sample injec-
tion, proteins were isocratically eluted at a flow rate of 0.8 ml/min.
Fractions of 0.2 ml were collected. Protein elution was monitored by
measuring the absorbance at 280 nm. The elution volume (in ml) of the
standard proteins were: tiroglobulin (669 kDa), 8.1; ferritin (440 kDa),
10.22; catalase (232 kDa), 12.11; ovalbumin (43 kDa), 14.73; chymotrip-
sin A (25 kDa), 18; ribonuclease A (13.7 kDa), 19. According to the
elution volume of the standard proteins, the estimated molecular mass
of the R265H MAT I/III rat mutant protein was 41 kDa. AdoMet
synthetic as well as tripolyphosphatase activities were measured in the
collected fractions.
Enzymatic Activity Measurements—Activity assays were performed
in a final volume of 100 ml, at 37 °C for 10 min in 50 mM Tris/HCl, pH
8, 4 mM MgCl2, 250 mM KCl, 3.6 mM DTT. 2 mM ATP/MgCl2 and
methionine or 2 mM tripolyphosphate were used as substrates to deter-
mine AdoMet synthetase or tripolyphosphatase activities, respectively.
Both activities were monitored by following the formation of inorganic
phosphate according to the method of Lanzetta (37). The effect of NO on
the tripolyphosphatase activity of the R265H mutant was determined
in the absence of DTT. Activation of the tripolyphosphatase activity by
substrates was studied by enzyme preincubation with 2 mM methionine
and 2 mM ATP.
RESULTS
Oligomeric State of the R265H MAT I/III Mutant Protein—
The molecular mass and catalytic properties of a purified
R265H MAT I/III mutant protein have been studied by size
exclusion chromatography. The elution volume of the R265H
MAT was 16 ml (Fig. 1), which corresponds to a molecular mass
of 41 kDa according to the elution profile of standard proteins.
This result suggests that this mutant protein is a monomeric
MAT.
Kinetics of the Monomeric R265H MAT I/III Mutant—To
test the enzymatic activity of the R265H MAT I/III mutant
protein, fractions were collected, and AdoMet synthetic activity
and tripolyphosphatase activity were measured. Interestingly,
the analysis of the R265H fractions revealed that, although no
AdoMet synthetic activity was detected, a tripolyphosphatase
activity peak was measured at the same elution volume as the
absorbance peak (Fig. 1). This result indicates that tripolypho-
sphate hydrolysis can be catalyzed by a single MAT subunit. In
contrast, AdoMet synthetic activity requires at least a dimeric
enzyme, since this active site is constituted between two
monomers.
The catalytic properties of the R265H MAT mutant were
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then further studied. MAT and tripolyphosphatase activities of
the MAT mutant R265H were measured at 2 mM of methionine
and ATP or tripolyphosphate (Fig. 2). Both activities were
determined as the accumulation of inorganic phosphate (Pi)
after incubation at 37 °C for different periods of time. Our data
indicate that while the Vmax for the tripolyphosphatase activity
of the R265H mutant was very similar to that determined for a
WT enzyme, AdoMet synthetic activity of this MAT variant was
decreased by more than 99% (Table I). Replacement of arginine
265 by serine instead of histidine resulted in a monomeric MAT
protein (data not shown) with more than 99% reduction of the
AdoMet synthetic activity and a 5-fold decrease in the tri-
polyphosphatase activity (Table I), suggesting that the positive
charge of the residue at position 265 is involved in the hydrol-
ysis of PPPi. Tripolyphosphatase activity of the R265H MAT
I/III mutant was dependent on Mg21 concentration, but K1
was not required (not shown). No change of tripolyphosphatase
specific activity was observed by increasing the protein concen-
tration (0.026–0.345 mg/ml). Additionally, to verify that the
monomer does not reassociate under assay conditions, a gel
filtration molecular mass determination in a column equili-
brated with 2 mM PPPi was performed. Under these conditions
the estimated molecular mass of the R265H MAT mutant was
41.6 kDa (not shown). These two lines of evidence indicate that
the monomeric state of this MAT mutant is maintained after
incubation with PPPi, and therefore, the tripolyphosphatase
activity of the R265H MAT mutant is not a consequence of
subunit dimerization. In contrast to WT protein, preincubation
with methionine and ATP did not stimulate the tripolyphos-
phatase activity (not shown). R265H tripolyphosphatase activ-
ity is specific for PPPi. Less than 2% of the hydrolytic activity
measured in the presence of PPPi was observed when ATP, PPi,
or metatripolyphosphate were used as substrates (Table II). No
significant changes of enzymatic activity or Km were detected
when the tripolyphosphatase activity of the R265H MAT I/III
mutant was tested in the presence of ATP (Fig. 3). However, a
decrease of the enzymatic activity from 128 to 67 nmol min21
mg21 was observed when the tripolyphosphatase activity was
measured in the presence of 2 mM PPi, a classical inhibitor of
the tripolyphosphatase activity of MAT (Fig. 3). Since the Hill
coefficient was always close to 1.0, the experimental data were
fitted to the Michaelis-Menten equation. The Km for PPPi was
increased from 84 to 143 mM when the tripolyphosphatase
activity was measured in the presence of PPi. NO regulates
hepatic MAT activity through specific interaction with cysteine
residue 121 (33, 38). To analyze the effect of NO on the tri-
polyphosphatase activity of the R265H MAT I/III mutant, the
enzyme was nitrosylated by incubation with 250 mM nitrosy-
lated glutathione before determining its capacity to hydrolyze
tripolyphosphate. No variations of the activity were observed
after nitrosylation of this enzyme. The enzymatic activities
were 125 and 129 nmol Pi min
21 mg21for the non-nitrosylated
and nitrosylated forms, respectively.
FIG. 1. Analysis by size exclusion chromatography of the
R265H MAT I/III mutant. The molecular mass of the His-tagged
R265H MAT I/III mutant, that had been purified by Ni21-Sepharose
column chromatogaphy, was estimated by size exclusion chromatogra-
phy on a Superdex 200 HR 10/30 column. —, absorbance profile at 280
nm. Fractions of 0.2 ml were collected and tripolyphosphatase (open
circles) and AdoMet (closed circles) activities were measured as de-
scribed under “Experimental Procedures.” The estimated molecular
mass of the R265H MAT mutant is 41 kDa.
FIG. 2. AdoMet synthetic and tripolyphosphatase activity of
the R265H MAT I/III mutant. Tripolyphosphatase (open circles) and
MAT (closed circles) activities of a purified R265H MAT I/III mutant
were measured by following the formation of Pi after incubation with
the substrates for different periods of time. Tripolyphosphatase and
MAT activity values were 129 and 2 nmol min21 mg21, respectively.
TABLE I
Enzymatic activity and estimated Km values for PPPi of mutants and
wild type recombinant rat liver MAT
Vmax
ATP,Met Vmax
PPPi Km
PPPi
nmol min21 mg21 mM
WT MAT 588 6 63 156 6 21 20 6 5
R265H MAT 2 6 0.23 128 6 13.7 83 6 6
R265S MAT 1 6 0.12 29 6 7.4 122 6 5
TABLE II
Substrate specificity of the monomeric MAT mutant R265H
Substrate concentration was 2 mM.
Enzymatic activity
nmol min21 mg21
PPPi 128 6 13
ATP 1.2 6 0.73
PPi 1.9 6 0.68
MP3 0.4 6 0.22
FIG. 3. Inhibition of the tripolyphosphatase activity of the
R265H MAT I/III mutant by PPi. The inhibition of tripolyphos-
phatase activity of the R265H MAT I/III mutant by ATP and PPi was
examined. Tripolyphosphatase activity of the R265H mutant was meas-
ured in the absence (open circles) and in the presence of 5 mM ATP
(closed circles) or 5 mM PPi (triangles). The experimental data were
fitted to the Michaelis-Menten equation. Values of Vmax and Km for PPPi
were 128 nmol min21 mg21 and 83 mM, respectively, in the absence of
any inhibitor; 67 nmol min21 mg21 and 143 mM, respectively, in the
presence of PPi; and 129 nmol min
21 mg21 and 78 mM, respectively, in
the presence of ATP.
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Association between WT and R265H Mutant MAT I/III Sub-
units—The capacity of the R265H MAT I/III mutant to form
hetero-oligomers with a WT subunit has been examined both in
vivo and in vitro, taking advantage of the N-terminal His-tag of
the mutant protein. If such an interaction occurred, mutant
and WT subunits would combine in a hetero-oligomeric form
that would be retained on a Ni21-Sepharose column. When
MAT purified from bacteria overexpressing WT and R265H
MAT subunit is chromatographed on a Ni21-Sepharose col-
umn, all the protein binds to the column, as shown by SDS-
PAGE analysis of the flow-through and the 0.5 M imidazole
eluted fraction (Fig. 4A). However, when the enzyme is un-
folded with urea before being reanalyzed by Ni21 chromatog-
raphy, the protein re-distributes between the flow-through and
retained fractions (Fig. 4B). Therefore, the original protein
must be a hetero-oligomer constituted by WT and His-tagged
mutant subunits.
Hetero-oligomeric formation was also demonstrated in vitro.
When MAT III was incubated with equimolar concentrations of
R265H mutant, the Ni21 column did not retain any MAT III
subunit, suggesting that there was no association between the
mutant and the rat liver protein after 30-min incubation (Fig.
5A). Alternatively, hetero-oligomer formation was attempted
under conditions more nearly approaching those that might
exist in vivo by refolding a urea-denatured MAT III in the
presence of the R265H mutant. After purification and urea
denaturation of the resulting His-tagged protein, the flow-
through and Ni21-retained fraction of a second Ni21-Sepharose
chromatography were analyzed by SDS-PAGE. Protein was
detected in both fractions (Fig. 5B), indicating that the His-
tagged purified protein was a hetero-oligomer consisting of
refolded MAT III and mutant (His-tagged) subunits.
Hybrid MAT Characterization—To estimate the molecular
mass of the hetero-oligomers resulting from cotransformed bac-
teria, size exclusion chromatography was performed, 0.4-ml
fractions were collected, and AdoMet synthetic and tripolypho-
sphatase enzymatic activities were measured. The estimated
molecular mass of MAT III purified from rat liver, which was
used as a control, was 91 kDa, according to the dimeric state of
this protein. Peaks of AdoMet synthetic and tripolyphos-
phatase activities were detected when fractions of MAT III
were analyzed (Fig. 6A). The molecular mass of the purified
hetero-oligomeric MAT was of 90 kDa, indicating its dimeric
nature. Similarly to MAT III, the protein-containing fractions
had tripolyphosphatase activity, but, in contrast, no AdoMet
synthetic activity was detected (Fig. 6B). Therefore, MAT pu-
rified by Ni21 chromatography from cotransfected bacteria is a
heterodimer with an impaired AdoMet synthetic capacity, al-
though its tripolyphosphatase activity is maintained. The ab-
sence of MAT activity in the heterodimeric WT R265H MAT
might explain the dominant inheritance of the phenotype as-
sociated with the R264H mutation described elsewhere (26). To
further assess the subunit composition of the heterodimeric
MAT, the flow-through and retained fractions resulting from a
Ni21-Sepharose chromatography of a denatured heterodimer
were analyzed by size exclusion chromatography. The imida-
zole-eluted protein had a molecular mass of 41 kDa and main-
tains the tripolyphosphatase activity, but no synthesis of
AdoMet was detected (Fig. 7A). The molecular mass, inability
to oligomerize, and the absence of AdoMet synthetic activity
indicate that this enzyme is the His-tagged R265H MAT mu-
tant. However, the protein obtained in the flow-through had a
molecular mass of 90 kDa, and both the tripolyphosphatase
and AdoMet synthetic activities were recovered (Fig. 7B).
These findings confirm that this protein is a non-His-tagged
WT MAT subunit that refolds and oligomerizes to get the
native, fully active conformation. Additionally, refolding of WT
MAT subunits in the presence of R265H MAT mutant results
in the formation of WT R265H heterodimers (not shown). It has
been shown previously that the tripolyphosphatase activity of
MAT III is activated by preincubation of the enzyme with the
FIG. 4. In vivo association between WT and His-tagged R265H
MAT mutant subunits. Proteins were obtained and purified as de-
scribed under “Experimental Procedures.” Hetero-oligomers were chro-
matographed on a Ni21-Sepharose column before (A) or after (B) dena-
turation with 5 M urea. The presence of MAT protein in the flow-
through fraction of the affinity column was indicative of association
between WT and His-tagged mutant subunits, which were eluted with
500 mM imidazole. Proteins were identified by SDS-PAGE. FT, flow-
through fraction from the Ni21-Sepharose column; R, fraction retained
on the Ni21-Sepharose column; Mr, molecular mass standards (bovine
serum albumin, 81 kDa; ovalbumin, 47.7 kDa; carbonic anhydrase, 34.6
kDa).
FIG. 5. In vitro association between MAT III purified from rat
liver and recombinant His-tagged R265H mutant subunits. As-
sociation between purified MAT III and R265H MAT mutant subunits
was analyzed under native conditions (A) or by refolding of MAT III in
the presence of mutant subunits (B). The obtained protein mixtures
were then denatured with 5 M urea and chromatographed on a Ni21-
Sepharose column. The presence of MAT in the flow-through fraction of
the affinity column was indicative of association between MAT III and
His-tagged mutant subunits, which were eluted with 500 mM imidazole.
Proteins were identified by SDS-PAGE. FT, flow-through fraction from
the Ni21-Sepharose column; R, fraction retained on the Ni21-Sepharose
column; Mr, molecular mass standards (standard proteins were the
same as in Fig. 4).
FIG. 6. Size exclusion chromatography of MAT III and hetero-
oligomeric MAT. The molecular mass of the hetero-oligomeric MAT
was estimated by size exclusion chromatography of the protein purified
by Ni21-Sepharose chromatography. —, absorbance profile at 280 nm.
Fractions of 0.4 ml were collected, and tripolyphosphatase (open circles)
and AdoMet synthetic (closed circles) activities were measured as de-
scribed under “Experimental Procedures.” A, rat liver MAT III. B,
hetero-oligomeric MAT. The estimated molecular mass for MAT III and
the hetero-oligomer was 90 kDa.
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substrates methionine and ATP (36). To test whether activa-
tion occurs also upon preincubation of the WT R265H het-
erodimeric MAT, the protein was pretreated with 2 mM methi-
onine and 2 mM ATP, and tripolyphosphatase activity was then
measured. No activation was observed after incubation of the
heterodimer with methionine and ATP. The activity values
were 132 and 134 nmol Pi min
21 mg21 for the non-preincu-
bated and preincubated forms, respectively. The absence of
activation of the heterodimeric MAT might be explained by a
deficient or non-productive interaction with the substrates.
This hypothesis would agree with the previous result, indicat-
ing that the synthesis of AdoMet is impeded in the
heterodimer.
DISCUSSION
Methionine adenosyltransferase catalyzes the synthesis of
AdoMet, the main alkylating agent in living cells (1). In the
liver, MAT is also responsible for the catabolism of up to 50% of
the dietary methionine (15). Humans with mutations in the
gene MAT1A have decreased MAT activities in the liver, re-
sulting in persistent hypermethioninemia without homocystin-
uria (22, 23). The hypermethioninemic phenotype associated
with all mutations tested to date is inherited as an autosomal
recessive trait, the only known exception being the hyperme-
thioninemia due to the G-A transition at nucleotide 791 of exon
VII (21–30). This change results in a mutant MAT1A-encoded
protein in which arginine 264 has been replaced by histidine
(26). To investigate the biochemical basis of the dominant in-
heritance of hypermethioninemia of individuals with this mu-
tation, we have studied the enzyme kinetics and the oligomer-
ization capacity of a purified MAT protein containing the
homologous R265H mutation encoded by rat MAT1A.
Our results indicate that the molecular mass of the R265H
MAT I/III rat mutant protein is 41 kDa, establishing its mono-
meric state. Although previous studies using cell extracts also
suggested that the equivalent R264H MAT I/III mutant protein
cannot form homo-oligomers (26, 39), it has been reported that
the tetrameric conformation of the E. coli MAT is not altered by
the replacement of the equivalent arginine 244 by histidine (4).
Our results demonstrate that the R265H MAT I/III rat mutant
has impaired ability to form homo-oligomers. Arginine 265,
similarly to arginine 244 in the E. coli MAT, is involved in a
salt bridge formation with symmetrical glutamic 58 (31, 32),
which is important for dimerization (40). Therefore, the ab-
sence of this arginine might compromise the dimerization ca-
pacity of this MAT mutant.
The synthetic reaction catalyzed by MAT occurs through two
consecutive steps. AdoMet and PPPi are first synthesized from
methionine and ATP; PPPi is subsequently hydrolyzed to PPi
and Pi to allow product release from the active site of the
enzyme (2, 3). The function of the tripolyphosphatase activity of
MAT is still under discussion (4, 41). MAT activity of the
R265H MAT I/III mutant was less than 1% of the activity of the
WT enzyme, in agreement with previous data, which indicate
that the active site of a dimeric MAT is configured by amino
acid residues from both subunits (31, 32, 40). However, the
tripolyphosphatase activity was not modified by this mutation,
indicating that the active site for this activity is fully func-
tional. Therefore, the hydrolytic site for the tripolyphosphatase
activity must be configured by residues held on a single sub-
unit. Tripolyphosphatase activity of this MAT mutant is simi-
lar to that determined for a WT enzyme in the resting, less
active state (36). Additionally, we found that tripolyphos-
phatase activity of the R265H MAT I/III mutant is not regu-
lated by NO, which further agrees with the mutant enzyme
being in the resting state. We have shown previously that
tripolyphosphatase activity of MAT III is stimulated by prein-
cubation with methionine and ATP (36). However, no activa-
tion of the tripolyphosphatase activity was found when R265H
MAT was preincubated with methionine and ATP, suggesting
that the regulation of this activity by the natural substrates of
the enzyme has been lost. The absence of AdoMet synthetic
activity, and the failure of methionine and ATP to activate the
tripolyphosphatase activity, suggest that binding of the sub-
strates is impaired. Substitution of arginine 265 by serine
instead of histidine resulted in a 5-fold decrease of tripolypho-
sphatase activity. Thus, it seems that, although the presence of
a positive charge at position 265 is involved, it is not an abso-
lute requirement for the PPPi hydrolytic activity. This result
might be explained by previous evidence, which indicates the
positive charge of the equivalent arginine 244 in the E. coli
MAT is responsible for the correct orientation of the PPPi in the
active site of the enzyme (4, 42).
Tripolyphosphatase activity of the R265H MAT I/III mutant
is specific of PPPi, and depends on the presence of Mg
21 in the
assay mixture, but K1 is not required. These findings suggest
that while Mg21 is directly involved in the binding of PPPi (31),
K1, which binds to the interface between monomers (40), might
contribute to the stabilization of a functional conformer of
dimeric MAT, which is not accessible to the monomeric R265H
mutant. This mutant showed no cooperativity when its tri-
polyphosphatase activity was assayed with different PPPi con-
centrations. Tripolyphosphatase activity of WT MAT is not
altered by the presence of saturating concentrations of ATP
(36). This finding might be explained by assuming that ATP
and PPPi bind to different sites, or, alternatively, binding of the
PPPi moiety of ATP might be sterically restricted in the dimeric
enzyme. To further assess this question, we studied the effect of
ATP on the tripolyphosphatase activity of the monomeric
R265H MAT mutant. We found that ATP had no effect on the
tripolyphosphatase activity of the R265H MAT I/III mutant.
FIG. 7. Size exclusion chromatography of heterodimeric MAT
subunits. Heterodimeric MAT purified from E. coli expressing WT and
His-tagged R265H mutant was denatured in 5 M urea, and the resulting
subunits were separated by chromatography on a Ni21-Sepharose col-
umn. The flow-through and retained fractions were analyzed by size
exclusion chromatography on a Superdex 200 HR 10/30 column equil-
ibrated without urea. A, retained fraction; B, flow-trough. —, absorb-
ance profile at 280 nm. Fractions of 0.4 ml were collected, and tri-
polyphosphatase (open circles) and AdoMet synthetic (closed circles)
activities were measured as described under “Experimental Proce-
dures.” The estimated molecular mass of the retained fraction and
flow-through was 41 and 90 kDa, respectively.
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Since accessibility should not be compromised in the monomer,
we propose that ATP and PPPi have different binding sites. In
contrast, PPi, a classical inhibitor of MAT tripolyphosphatase
activity, induces a 1.5- and 2.3-fold decrease of the enzymatic
activity and affinity of the enzyme, respectively. Similarly to E.
coli MAT (43), PPi and PPPi might compete for the same bind-
ing site. Our data suggest that the active site of MAT has two
coordinated subsites: the synthetic site, configured by amino
acid residues from both subunits (31, 32), is responsible for the
binding of methionine and ATP and performs the AdoMet syn-
thetic reaction. The hydrolytic site, configured by amino acid
residues from one single subunit, accounts for the binding of
PPPi and performs the PPPi hydrolytic reaction.
Dominant inheritance of the hypermethioninemia of humans
carrying the R264H mutation in MAT1A might be explained by
our findings, which indicate that replacement in the rat homo-
logue of arginine 265 by histidine produces a monomeric MAT
that interacts with the WT MAT subunit, in vivo and in vitro,
resulting in a hybrid enzyme with impaired AdoMet synthetic
activity. Evidence suggesting the capacity of the MAT mutant
R264H to associate with WT MAT was first proposed for the
human enzyme by Chamberlin et al. (26) on the basis of MAT
activity recovered in COS cell extracts after cotransfection with
two vectors expressing human R264H mutant and WT MAT,
respectively. We have demonstrated that MAT enzyme purified
by Ni21-Sepharose chromatography from E. coli cotransformed
with plasmids expressing rat R265H mutant and WT MAT is a
hetero-oligomer, which is formed by mutant and WT subunits.
In contrast, when MAT III purified from rat liver was incu-
bated with the recombinant rat R265H MAT I/III mutant, no
association was observed under the experimental conditions
used in our studies. This apparent discrepancy might be ex-
plained by assuming that the dissociation constant for the
dimer is sufficiently low to prevent MAT III-mutant subunit
exchange under our experimental conditions. Since monomers
generally fold to nearly the final conformation before the asso-
ciation step (44), association between MAT subunits may occur
at a late intermediate step of the folding process. Indeed, we
found that a hybrid MAT, containing WT and mutant subunits,
was formed when a urea-unfolded MAT III purified from rat
liver was refolded in the presence of the R265H MAT I/III
mutant. The presence of urea might overcome the proposed
kinetic restrictions, allowing subunit exchange either by in-
creasing the dimer Kd or by altering the protein conformation.
To estimate the oligomeric state of the hetero-oligomeric
MAT species, size exclusion chromatography studies were per-
formed, and fractions were collected to determine their cata-
lytic capacity. The calculated molecular mass of MAT III was
91 kDa in agreement with its dimeric structure (5), and
AdoMet synthetic as well as tripolyphosphatase activities were
found when the protein-containing fractions were assayed. The
hetero-oligomeric MAT purified from E. coli expressing WT and
R265H MAT mutant has a molecular mass of 90 kDa. Since
this MAT was previously retained on a Ni21-Sepharose col-
umn, and the R265H MAT I/III mutant has lost the ability to
form homo-oligomers, the 90-kDa protein must correspond to a
heterodimer containing one R265H mutant (His-tagged) and
one WT subunit. The heterodimer might be stabilized by the
salt bridge interaction between arginine 265 in the WT subunit
and glutamic 58 in the mutant subunit. The heterodimeric
MAT maintains the tripolyphosphatase activity, but no synthe-
sis of AdoMet was determined after incubation with methio-
nine and ATP. This lack of AdoMet synthetic activity might be
a consequence of a non-native association between monomers,
resulting in an altered active site and, consequently, in a defi-
cient substrate binding or catalytic capacity of the heterodimer.
This hypothesis is further supported by the finding that, in
contrast to WT enzyme (36), tripolyphosphatase activity of the
R265H-WT MAT is not activated when the enzyme is preincu-
bated with methionine and ATP. The ability of the monomeric
R265H MAT I/III mutant to associate with a WT subunit,
resulting in a hybrid WT R265H MAT without AdoMet syn-
thetic activity, might explain the dominant inheritance of the
hypermethioninemia associated with the human R264H MAT
I/III mutation. Additionally, denaturation of heterodimeric
MAT by incubation with 5 M urea results in two forms of the
enzyme, which were separated by Ni21 chromatography, and
showed different molecular mass and enzymatic activities upon
refolding. The retained fraction was a monomer (41 kDa) with
tripolyphosphatase activity, and the flow-through was a dimer
(90 kDa) with both tripolyphosphatase and AdoMet synthetic
activity as determined by size exclusion chromatography. Ac-
cording to their properties, these two forms of MAT must be
identified as refolded His-tagged, monomeric R265H mutant
and dimeric, fully active WT MAT. These findings indicate that
urea unfolding of MAT is a reversible process and further
support that MAT purified from E. coli expressing WT and
R265H MAT mutant is a heterodimer constituted by WT and
mutant subunits.
In conclusion, our data provide a molecular explanation for
the dominant inheritance of the persistent hypermethionine-
mia associated with the human R264H MAT I/III mutation. We
demonstrate that the equivalent R265H mutation in rat MAT
I/III results in a monomeric MAT, which can associate with the
WT enzyme to form a dimeric R265H-WT MAT lacking AdoMet
synthetic activity. We have also shown that the active site for
the tripolyphosphatase activity is functionally active in the
monomeric R265H MAT I/III mutant. Our data suggest that
the active site of MAT has two coordinated subsites: the syn-
thetic site, configured by amino acid residues from both sub-
units, that performs the AdoMet synthetic reaction, and the
hydrolytic site, configured by amino acid residues from one
single subunit, that performs the PPPi hydrolytic reaction.
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